Summit Therapeutics Inc.
No SEC Form 4 filings for $SMMT in the last 30 days.
See all $SMMT insider activity →Akeso Inc. (9926.HK) and Summit Therapeutics (SMMT) will present data on ivonescimab, an experimental cancer treatment, at ESMO 2026. Positive Phase III results for advanced biliary tract cancer and data on other tumor types will be shared. Ivonescimab is in multiple Phase III trials, with over 5,000 patients treated globally.
Summit Therapeutics (SMMT) partners with ECOG-ACRIN for a Phase II/III trial of ivonescimab plus chemo against pembrolizumab or durvalumab plus chemo for advanced biliary tract cancer. The trial is expected to start in Q4 2026, following positive data from China. This expands ivonescimab's potential beyond NSCLC.
Summit Therapeutics and Akeso are collaborating on a Phase II study (SMT112-216) to evaluate ivonescimab alone and in combination with other treatments for advanced kidney cancer. The study aims to enroll 100 patients and assess the safety and efficacy of ivonescimab-based regimens. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, is being studied in multiple Phase III trials. Summit's shares trade on Nasdaq under the symbol SMMT.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning SMMT (Summit Therapeutics Inc.). Coverage has skewed bullish: 7 bullish, 4 neutral, and 0 bearish.
Recent SMMT coverage spans financial news, market movers and technology.
Positive survival data in a late‑breaking Phase III trial is likely to boost investor sentiment and drive the stock higher.
The collaboration creates a registration‑enabling trial that could drive a significant upside if data are positive.
The trial adds to Summit's pipeline and may affect near‑term valuation as investors price early‑stage risk and potential upside.
The stock is under short‑term pressure with downside bias.
The stock is under pressure from profit‑taking and heightened regulatory risk concerns.
AlphAI scores every news story that mentions SMMT with an AI model for sentiment and relevance, and aggregates insider trades from Summit Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Akeso Inc. (9926.HK) and Summit Therapeutics (SMMT) will present data on ivonescimab, an experimental cancer treatment, at ESMO 2026. Positive Phase III results for advanced biliary tract cancer and data on other tumor types will be shared. Ivonescimab is in multiple Phase III trials, with over 5,000 patients treated globally.
2 min readSummit Therapeutics (SMMT) partners with ECOG-ACRIN for a Phase II/III trial of ivonescimab plus chemo against pembrolizumab or durvalumab plus chemo for advanced biliary tract cancer. The trial is expected to start in Q4 2026, following positive data from China. This expands ivonescimab's potential beyond NSCLC.
1 min readSummit Therapeutics and Akeso are collaborating on a Phase II study (SMT112-216) to evaluate ivonescimab alone and in combination with other treatments for advanced kidney cancer. The study aims to enroll 100 patients and assess the safety and efficacy of ivonescimab-based regimens. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, is being studied in multiple Phase III trials. Summit's shares trade on Nasdaq under the symbol SMMT.
2 min readSummit Therapeutics (SMMT) shares fell 6.89% as investors 'sell the news' after AstraZeneca's $2B investment. Traders await pivotal cancer drug data. Confusion with unrelated SMMT acronym added volatility. No new price targets. Long-term prospects depend on trial success and financing.
1 min readSummit Therapeutics (SMMT) shares fell 5.07% due to profit-taking after a rally linked to AstraZeneca's $2B investment, broader biotech weakness, and analyst doubts about ivonescimab's FDA approval chances. The company has no revenue and is burning cash on trials, with a market cap of $13.81B.
1 min readSummit Therapeutics (SMMT) shares rose after announcing a clinical collaboration with AstraZeneca and Daiichi Sankyo for its cancer drug, ivonescimab. AstraZeneca invested $2B at $18.36 per share. The company awaits an FDA decision in 2026, with strong Phase III results reported. Summit remains pre-revenue, facing regulatory and cash burn risks.
2 min readBernstein reiterated a Market Perform rating and $11.90 price target for Summit Therapeutics (NASDAQ:SMMT), citing concerns about FDA approval for a treatment regimen combining Datroway and Ivonescimab. The stock trades at $16.75, with a market cap of $13.4 billion. Bernstein assigned low probabilities for technical success in Phase 3 trials. Summit announced a $2 billion investment from AstraZeneca, with several firms reiterating their ratings and price targets.
1 min readSummit Therapeutics (SMMT) completed a $2.0B equity investment from AstraZeneca, involving preferred stock convertible at $18.36 per share. The funds will support the development of ivonescimab, a drug with a near-term regulatory catalyst.
1 min readWall Street ended mixed as jobs data reduced Fed rate-hike odds, but Treasury yields rose. MongoDB MDB fell after CEO departure. Nvidia NVDA boosted buyback by $150B. Micron MU beat Q4 expectations. Summit SMMT surged on AstraZeneca AZN $2B investment. Nike NKE missed sales. SpaceX SPCX gained on milestones. Corteva CTVA spun off seed business. Seagate STX and Western Digital WDC dropped on Toshiba TSHTY supply news.
3 min readSummit Therapeutics partners with AstraZeneca and Daiichi Sankyo to develop a cancer drug. The collaboration includes a $50 million milestone payment to Eccogene. The companies will test the drug in clinical trials. The deal may impact Summit's stock as it advances the cancer treatment.
1 min read
